Market Overview

CICC Raises Price Target on Mindray Medical Following Management Meeting

Related MR
Earnings Scheduled For November 3, 2014
Benzinga's Volume Movers

China International Capital raised its price target on Mindray Medical (NYSE: MR) from $37.00 to $44.00 and maintained a Buy rating on the stock.

In the report, China International Capital stated, "Management shed more light on the 2013 outlook, where China and Emerging markets will remain the key growth drivers, while developed markets hold strategic value despite their minor contribution to near term profitability."

Mindray Medical closed Wednesday at $37.69.

Latest Ratings for MR

DateFirmActionFromTo
May 2014JefferiesAssumesHold
May 2014Bank of AmericaDowngradesBuyNeutral
Apr 2014Credit SuisseUpgradesUnderperformNeutral

View More Analyst Ratings for MR
View the Latest Analyst Ratings

Posted-In: China International Capital Corp.Analyst Color Price Target Analyst Ratings

 

Related Articles (MR)

Around the Web, We're Loving...

Get Benzinga's Newsletters